Neogen Chemicals Limited will participate in an analysts and investors group meeting on Tuesday, September 22, 2026. The session is scheduled for 2:00 pm at Trident BKC in Mumbai.

The event is part of Morgan Stanley’s Energy Security and Powering AI Field Trip. Management will discuss the company’s business overview, financial performance, and outlook.

Meeting Details

Regulatory Disclosure

The intimation was issued pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Unnati Kanani, Company Secretary and Compliance Officer, signed the disclosure.

The company stated that no unpublished price-sensitive information will be shared during the meeting. The date and participants are subject to change due to exigencies.

Further details are available on the company’s website.

Neogen Chemicals closed its qualified institutional placement (QIP) on September 16, 2026, raising ₹5,99,99,98,015 by allotting 26,60,753 equity shares at ₹2,255 per share. The Fund-Raising Committee approved the final price and closure of the issue period on that date.

The company allotted the shares to eligible qualified institutional buyers. The issue opened on September 10, 2026, with a floor price of ₹2,189.73 per share. The allotment increases the company’s paid-up equity share capital from ₹27,38,16,740 (2,73,81,674 shares) to ₹30,04,24,270 (3,00,42,427 shares).

Pricing and Regulatory Framework

The final issue price was determined in consultation with the lead managers appointed for the issue. The price includes a premium of ₹2,245 per share over the face value of ₹10.

The QIP was conducted in terms of Chapter VI of the SEBI ICDR Regulations and Section 42 and Section 62 of the Companies Act, 2013. The preliminary placement document was approved on September 10, 2026, while the final placement document dated September 16, 2026, has been filed with both BSE Limited and the National Stock Exchange of India Limited.

Allotment Details

The Board of Directors initially approved the issue in its meeting held on July 24, 2026. Shareholders subsequently granted approval through a special resolution passed on August 21, 2026.

The confirmation of allocation note has been finalized and sent to eligible qualified institutional buyers. The equity shares allotted rank pari passu with existing equity shares in all respects, including dividend and voting rights.

Major allottees receiving more than 5% of the equity shares offered in the issue include:

Other significant investors include Mirae Asset funds, WhiteOak Capital funds, and Axis Mutual Fund schemes. The list of allottees is available in Annexure 1 of the regulatory filing.

Issue Mechanics

The placement document is available on the company’s website under the Issue of Securities tab. The same has been taken on record and disseminated to all concerned as per SEBI Listing Obligations and Disclosure Requirements Regulations.